MENU

Cochlear faces potential price competition in China

Cochlear (ASX: COH) shares were down 4.8% on Thursday as investors considered potential threats to its Chinese market dominance. The Aussie world-beater has long been a beneficiary of the fast-growing Chinese healthcare market, however, the potential for increased competition saw a share price slide yesterday.

Media reports that Chinese company Nurotron Biotechnology will compete for lucrative government contracts on a low-cost basis are what spooked investors. Cochlear, though, bases its product price premium on industry-leading products in hearing loss healthcare.

It is not the first multi-national to face product competition from enterprising Chinese companies and it will continue to rely on its best-in-class reputation and technological edge to translate into increasing profits across global markets.

The company recently launched its latest hearing device, the Nucleus N6. It is said to be the start of an innovative new range of sound processing technologies, which it thinks will keep it ahead of the competition through 2014 and beyond.

Foolish takeaway

Home-grown competitors in foreign markets will always exist as a risk for Cochlear. Its competitive advantage lies with its technology, and maintaining this long-term should keep the future bright.

Interested in our #1 dividend-paying stock? Discover The Motley Fool’s favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of “The Motley Fool’s Top Dividend Stock for 2013-2014.”

More reading


Motley Fool contributor Tom Richardson owns shares Cochlear.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.